Published in Vaccine on May 19, 2008
Heterologous prime-boost vaccination. Curr Opin Immunol (2009) 1.84
Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44
Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine (2010) 1.38
Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One (2011) 1.03
Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS One (2011) 0.99
Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine (2011) 0.93
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One (2012) 0.93
Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. PLoS One (2011) 0.92
Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One (2011) 0.92
Impact of immunization technology and assay application on antibody performance--a systematic comparative evaluation. PLoS One (2011) 0.91
Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm (2012) 0.88
Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. Vaccines (Basel) (2013) 0.88
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med (2011) 0.87
DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther (2012) 0.87
Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum Vaccin Immunother (2013) 0.86
Prime-boost immunization using a DNA vaccine delivered by attenuated Salmonella enterica serovar typhimurium and a killed vaccine completely protects chickens from H5N1 highly pathogenic avian influenza virus. Clin Vaccine Immunol (2010) 0.85
Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One (2012) 0.84
Identification of Aim2 as a sensor for DNA vaccines. J Immunol (2014) 0.83
Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Control Release (2013) 0.82
A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. J Immunol (2015) 0.82
Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses. Hum Vaccin Immunother (2014) 0.81
Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity. J Transl Med (2010) 0.80
New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens. Virology (2009) 0.80
Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization. Hum Vaccin Immunother (2013) 0.79
Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine. Vaccines (Basel) (2013) 0.78
DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus. Hum Vaccin Immunother (2013) 0.78
Mucosal vaccines against respiratory syncytial virus. Curr Opin Virol (2014) 0.77
DNA immunization. Curr Protoc Microbiol (2013) 0.76
Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines (2015) 0.75
Technical transformation of biodefense vaccines. Vaccine (2009) 0.75
DNA immunization as a technology platform for monoclonal antibody induction. Emerg Microbes Infect (2016) 0.75
Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine. Vaccine (2016) 0.75
Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A (1999) 14.90
Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 12.95
A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A (2000) 12.16
Rescue of influenza A virus from recombinant DNA. J Virol (1999) 11.54
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet (2006) 5.72
Influenza: old and new threats. Nat Med (2004) 5.35
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
H5N1 influenza--continuing evolution and spread. N Engl J Med (2006) 4.47
Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine (2002) 4.45
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet (2006) 4.22
Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol (2004) 3.81
An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci U S A (2005) 2.33
Plasmid-only rescue of influenza A virus vaccine candidates. Philos Trans R Soc Lond B Biol Sci (2001) 2.28
The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine (2003) 2.11
Influenza vaccines: present and future. J Clin Invest (2002) 1.74
A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol (1997) 1.65
Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine (2005) 1.37
Low antigen dose favours selection of somatic mutants with hallmarks of antibody affinity maturation. Immunology (1998) 0.95
Immune response of neonates elicited by somatic transgene vaccination with naked DNA. Front Biosci (1997) 0.85
Influenza: vaccination still the best protection. FDA Consum (2007) 0.81
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol (2007) 7.18
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 5.47
Human host factors required for influenza virus replication. Nature (2010) 5.28
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A (2003) 5.05
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4.79
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A (2006) 4.58
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol (2005) 4.31
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol (2005) 4.16
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A (2009) 4.12
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A (2007) 3.98
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci U S A (2009) 3.91
Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci U S A (2004) 3.85
Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe (2009) 3.79
Gain-of-function experiments on H7N9. Science (2013) 3.67
Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol (2007) 3.53
Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog (2005) 3.44
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol (2011) 3.32
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A (2010) 3.17
Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science (2007) 3.16
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses (2012) 3.04
Influenza A viruses: new research developments. Nat Rev Microbiol (2011) 3.00
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol (2006) 2.94
Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol (2005) 2.88
Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A (2010) 2.81
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol (2008) 2.56
NS5 of dengue virus mediates STAT2 binding and degradation. J Virol (2009) 2.42
Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome. Clin Infect Dis (2011) 2.34
Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A (2007) 2.33
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Pause on avian flu transmission research. Science (2012) 2.24
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A (2006) 2.23
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Identification of cellular interaction partners of the influenza virus ribonucleoprotein complex and polymerase complex using proteomic-based approaches. J Proteome Res (2007) 2.21
Suppression of the antiviral response by an influenza histone mimic. Nature (2012) 2.18
Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol (2010) 2.17
Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol (2010) 2.17
Hemorrhagic fever caused by a novel tick-borne Bunyavirus in Huaiyangshan, China. Zhonghua Liu Xing Bing Xue Za Zhi (2011) 2.15
The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J Virol (2002) 2.14
Transmission of influenza virus via aerosols and fomites in the guinea pig model. J Infect Dis (2009) 2.12
Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis (2003) 2.05
PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J Virol (2010) 2.01
Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol (2004) 1.98
Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol (2005) 1.96
Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling. Cell Host Microbe (2013) 1.95
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol (2007) 1.95
The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol (2010) 1.94
The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol (2007) 1.93
Reverse genetics studies on the filamentous morphology of influenza A virus. J Gen Virol (2003) 1.92
Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol (2010) 1.92
Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry (2007) 1.89
Virulence determinants of pandemic influenza viruses. J Clin Invest (2011) 1.87
Complete-proteome mapping of human influenza A adaptive mutations: implications for human transmissibility of zoonotic strains. PLoS One (2010) 1.87
Early outcomes of active surveillance for localized prostate cancer. BJU Int (2005) 1.84
Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc Natl Acad Sci U S A (2006) 1.83
The M segment of the 2009 new pandemic H1N1 influenza virus is critical for its high transmission efficiency in the guinea pig model. J Virol (2011) 1.82
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. J Virol (2010) 1.81
Influenza A virus-generated small RNAs regulate the switch from transcription to replication. Proc Natl Acad Sci U S A (2010) 1.77
Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J Virol (2004) 1.77
Novel method for high-throughput phenotyping of sleep in mice. Physiol Genomics (2006) 1.77
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res (2007) 1.75
Influenza vaccines: present and future. J Clin Invest (2002) 1.74
Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J Virol (2008) 1.73
Viruses and the type I interferon antiviral system: induction and evasion. Int Rev Immunol (2002) 1.73
Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol (2006) 1.73
Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet (2005) 1.72
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol (2010) 1.72
Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med (2008) 1.72